Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

prnasiaJuly 08, 2020

Tag: therapeutics , Zai Lab , Repotrectinib

PharmaSources Customer Service